



CHARITY COMMISSION FOR ENGLAND AND WALES

Independent examiner's report on the accounts

Section A

Independent Examiner's Report

Report to the trustees/
members of

Charity Name

Chronic Lymphocytic Leukaemia Support Association UK (CLLSA)

On accounts for the year
ended

31 December 2025

Charity no
(if any)

1178482

Set out on pages

(remember to include the page numbers of additional sheets)

I report to the trustees on my examination of the accounts of the above charity ("the Trust") for the year ended 31/12/25.

Responsibilities and
basis of report

As the charity trustees of the Trust, you are responsible for the preparation of the accounts in accordance with the requirements of the Charities Act 2011 ("the Act").

I report in respect of my examination of the Trust's accounts carried out under section 145 of the 2011 Act and in carrying out my examination, I have followed the applicable Directions given by the Charity Commission under section 145(5)(b) of the Act.

Independent
examiner's statement

I have completed my examination. I confirm that no material matters have come to my attention (other than that disclosed below *) in connection with the examination which gives me cause to believe that in, any material respect:

- accounting records were not kept in accordance with section 130 of the Act or
- the accounts do not accord with the accounting records

I have no concerns and have come across no other matters in connection with the examination to which attention should be drawn in order to enable a proper understanding of the accounts to be reached.

** Please delete the words in the brackets if they do not apply.*

Signed:

Andy Davis

Date:

30.4.26.

Name:

Andy Davis FCA

Relevant professional
qualification(s) or body
(if any):

Institute of Chartered Accountants in England and Wales (ICAEW)

Address:

The Old Post Office, 41-43 Market Place

Chippenham

SN15 3HR

Only complete if the examiner needs to highlight matters of concern (see CC32, Independent examination of charity accounts: directions and guidance for examiners).

Give here brief details of any items that the examiner wishes to disclose.



**CHARITY COMMISSION
FOR ENGLAND AND WALES**

Trustees' annual report (including Directors' report)

for the period from: 01 January 2025 to 31 December 2025

Charity name: Chronic Lymphocytic Leukaemia Support Association UK (CLLSA)

Charity registration number: 1178482

Objectives and activities

	SORP reference	
Summary of the purposes of the charity as set out in its governing document	Para 1.17	<p>1. To relieve sickness and to preserve and protect health by providing support to chronic lymphocytic leukaemia (CLL) patients and their carers. (CLL includes similar related conditions such as SLL).</p> <p>2. To advance public education in CLL related matters primarily in the UK through publications and the internet.</p> <p>3. To promote and support scientific research into the treatment and care of all CLL patients.</p>
Summary of the main activities in relation to those purposes for the public benefit, in particular, the activities, projects or services identified in the accounts.	Para 1.17 and 1.19	<p>1. The provision of up to date and accessible information about CLL, the range of treatments currently available and the latest research into the care and treatment of CLL, through the Charity's website, webinars, member conferences, publications and a telephone helpline.</p> <p>2. The development of opportunities to share understanding and personal experience by bringing CLL patients together, and by creating mutual support groups and networks.</p> <p>3. Acting as a voice for CLL patients, representing their interests with the pharmaceutical industry, clinicians, NHS, cancer care policy and drug regulatory authorities, funding and commissioning groups and Government.</p> <p>4. The promotion of an awareness of CLLSA, together with its role amongst health care providers and decision makers, providers of non-healthcare products and services, other blood cancer patient groups and the wider public.</p>

Statement confirming whether the trustees have had regard to the guidance issued by the Charity Commission on public benefit	Para 1.18	In undertaking these activities, the Trustees confirm that they have had regard to the guidance issued by the Charity Commission on the matter of public benefit.
------------------------------------------------------------------------------------------------------------------------------	-----------	-------------------------------------------------------------------------------------------------------------------------------------------------------------------

Additional information (optional)

You may choose to include further statements where relevant about:

	SORP reference	
Policy on grant making	Para 1.38	
Policy on social investment including program related investment	Para 1.38	
Contribution made by volunteers	Para 1.38	
Other		

Achievements and performance

Summary of the main achievements of the charity, identifying the difference the charity's work has made to the circumstances of its beneficiaries and any wider benefits to society as a whole.	Para 1.20	<p>Every member of the Board of Trustees has been affected personally by CLL, either as a patient or through a close personal relationship with a patient, and accordingly is well placed to judge the needs of CLL patients and their supporters.</p> <p>With the assistance of two dedicated part time members of staff, every individual Trustee is both directly and heavily involved in the delivery of the support services that the Charity has to offer.</p> <p>In the last year the Charity has</p> <ol style="list-style-type: none"> 1. Run in-person member conferences as well as continuing to provide online webinar presentations. The events continue to be fronted by many of the leading experts in the field of the treatment of CLL. 2. Continued its close collaboration with the UK CLL Forum, thus helping the Forum to bridge the gap between Scientists, Clinicians and Patients. 3. Continued its work with the Blood Cancer Alliance and with Cancer52 to promote the interests of those suffering from blood cancers in general, and from CLL in particular.
-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------	-----------	----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

		<p>4. Continued with the development and roll out of its Support ACT programme, offering users access to guidance and support to help improve the well-being of CLL patients and their immediate supporters.</p> <p>5. Continued to maintain a telephone helpline service that is available to offer immediate support and guidance to CLL patients and their supporters.</p> <p>6. Continued to participate in partnering arrangements with major pharmaceutical companies designed to offer those companies key insights into the way in which treatments for CLL impact on the lives and wellbeing of patients.</p> <p>7. Continued to benefit from donations and fundraising activities that were undertaken by its supporters.</p> <p>8. Continued to benefit from funding provided by the pharmaceutical industry.</p>
--	--	------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

Additional Information (optional)

You may choose to include further statements where relevant about:

Achievements against objectives set	Para 1.41	
Performance of fundraising activities against objectives set	Para 1.41	

Investment performance against objectives	Para 1.41	
Other		

Financial review

Review of the charity's financial position at the end of the period	Para 1.21	
Statement explaining the policy for holding reserves stating why they are held	Para 1.22	<p>The Charity aims to maintain total reserves that would be the equivalent of 18 months of its anticipated normal level of annual running costs. Should it be that circumstances arise which resulted in a significant loss of incoming financial resources, that level of reserves would enable the Charity to continue to provide essential support services to CLL patients and their supporters for an extended, transitional period of time.</p> <p>The Trustees have also agreed that, as a minimum, an amount that is the equivalent of between 12 and 18 months' planned expenditure should be held in the form of liquid reserves to ensure both continued financial security and to provide for contingencies.</p> <p>In determining these figures, the Trustees have considered the need to hold back some funds as reserves, using the categories set out in the Charity Commission Guidance Document CC19: <i>Charity reserves: building resilience</i>.</p>
Amount of reserves held	Para 1.22	At the end of the period the Charity held reserves of £319,104.
Reasons for holding zero reserves	Para 1.22	N/A
Details of fund materially in deficit	Para 1.24	None
Explanation of any uncertainties about the charity continuing as a going concern	Para 1.23	None in the immediately foreseeable future

Additional Information (optional)

You may choose to include further statements where relevant about:

The charity's principal sources of funds (including any fundraising)	Para 1.47	
Investment policy and objectives including any social investment policy adopted	Para 1.46	
A description of the principal risks facing the charity	Para 1.46	
Other		

Structure, governance and management

Description of charity's trusts:		
Type of governing document:	Para 1.25	Trust Deed dated 22 nd May 2018
How is the charity constituted?	Para 1.25	Charitable Incorporated Organisation
Trustee selection method including details of any constitutional provisions	Para 1.25	Election by a majority of the existing Trustees

Additional information (optional)

You may choose to include further statements where relevant about:

Policies and procedures adopted for the induction and training of trustees	Para 1.51	
The charity's organisational structure and any wider network with which the charity works	Para 1.51	
Relationship with any related parties	Para 1.51	
Other		

Reference and administrative details

Charity name	Chronic Lymphocytic Leukaemia Support Association UK (CLLSA)
Other name the charity uses	(i) CLL Support (ii) CLL Support Association
Registered charity number	1178482
Charity's principal address	Sulte 112 - 8 The Bridge, Chippenham, Wilts. SN15 1FY

Names of the charity trustees who manage the charity

	Trustee name	Office (if any)	Dates acted if not for whole year	Name of person (or body) entitled to appoint trustee (if any)
1	Allen, Peter	Chair from 13.04.26		
2	Grant, Norah			
3	Greensmyth, John			
4	Holland, Anthea			
5	Lindsay, Hilary	Chair to 13.04.26		
6	Rawlings, Stephen	Treasurer	From 13.10.25 to 31.12.25	

7	Richardson, Suzanne		From 01.09.25 to 31.12.25	
8	Sulters, Steffi		01.01.25 to 14.04.25	
9	Van de l'Isle, Marianne		From 01.09.25 to 31.12.25	
10	Van de l'Isle, Troy		From 01.09.25 to 31.12.25	
11	Yates, Debra			

Corporate trustees – names of the directors at the date the report was approved

Director name	
	N/A

Name of trustees holding title to property belonging to the charity

Trustee name	Dates acted If not for whole year
	N/A

Funds held as custodian trustees on behalf of others

Description of the assets held in this capacity	None
Name and objects of the charity on whose behalf the assets are held and how this falls within the custodian charity's objects	N/A
Details of arrangements for safe custody and segregation of such assets from the charity's own assets	N/A

Additional Information (optional)

Names and addresses of advisers (optional information)

Type of adviser	Name	Address

Name of chief executive or names of senior staff members (optional information)

--

Exemptions from disclosure

Reason for non-disclosure of key personnel details

--



Declarations

The company has taken advantage of the small companies' exemption in preparing the report above.

The trustees declare that they have approved the trustees' report (including directors' report) above.

Signed on behalf of the charity's trustees/directors

Signature(s)

	
Hilary Lindsay	Stephen Rawlings
Trustee	Trustee Treasurer

Full name(s)

Position

Date

	24/05/26	
--	----------	--



CHARITY COMMISSION
FOR ENGLAND AND WALES

Charity Name
Chronic Lymphocytic Leukaemia Support Association U
No (if any)
1178482

Receipts and payments accounts

CC16a

For the period from	Period start date 01/01/2025	To	Period end date 31/12/2025
------------------------	---------------------------------	----	-------------------------------

Section A Receipts and payments

	Unrestricted funds to the nearest £	Restricted funds to the nearest £	Endowment funds to the nearest £	Total funds to the nearest £	Last year to the nearest £
A1 Receipts					
Donations	94,280	-	-	94,280	138,427
Grants	100	81,160	-	81,260	60,000
Gift Aid	7,084	-	-	7,084	5,928
Bank and deposit interest	7,230	-	-	7,230	16,485
	-	-	-	-	-
	-	-	-	-	-
	-	-	-	-	-
Sub total (Gross income for AR)	108,674	81,160	-	189,834	220,840
A2 Asset and Investment sales, (see table).					
	850	-	-	850	931
	-	-	-	-	-
Sub total	850	-	-	850	931
Total receipts	109,524	81,160	-	190,684	221,771
A3 Payments					
Support work	75,507	79,160	-	154,667	129,567
Administration	51,144	-	-	51,144	59,333
Fundraising	10,745	-	-	10,745	22,255
	-	-	-	-	-
	-	-	-	-	-
	-	-	-	-	-
	-	-	-	-	-
Sub total	137,396	79,160	-	216,556	211,155
A4 Asset and Investment purchases, (see table)					
	-	-	-	-	-
Sub total	-	-	-	-	-
Total payments	137,396	79,160	-	216,556	211,155
Net of receipts/(payments)	- 27,872	2,000	-	- 25,872	10,616
A5 Transfers between funds	-	-	-	-	-
A6 Cash funds last year end	287,483	-	-	287,483	276,867
Cash funds this year end	259,611	2,000	-	261,611	287,483

Section B Statement of assets and liabilities at the end of the period

Categories	Details	Unrestricted funds to nearest £	Restricted funds to nearest £	Endowment funds to nearest £
B1 Cash funds	Bank etc balances	259,206	2,000	-
	Held by donation portals	405	-	-
		-	-	-
	Total cash funds	259,611	2,000	-
	(agree balances with receipts and payments account(s))			



	Unrestricted funds to nearest £	Restricted funds to nearest £	Endowment funds to nearest £
B2 Other monetary assets			
Accrued bank interest	1,419	-	-
Prepaid expenses	804	-	-
Gift Aid claim	3,174	-	-
	-	-	-
	-	-	-
	-	-	-

	Details	Fund to which asset belongs	Cost (optional)	Current value (optional)
B3 Investment assets	Quoted investment holdings	Unrestricted	-	67,493
			-	-
			-	-
			-	-
			-	-
			-	-

[illegible]

	Details	Fund to which liability relates	Amount due (optional)	When due (optional)
B5 Liabilities	Creditors & accrued expenses	Unrestricted fund	4,815	
			.	
			.	
			.	
			.	

Signed by one or two trustees on behalf of all the trustees

Signature	Print Name	Date of approval
	Stephen Rawlings	16/02/2026
	Hilary Lindsay	16/02/2026
2		30/04/2026